Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.52 EUR | +1.28% | +1.49% | +34.84% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- With a P/E ratio at 11.16 for the current year and 9.44 for next year, earnings multiples are highly attractive compared with competitors.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.78 for the current period. Therefore, the company is undervalued.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company sustains low margins.
- The company is in debt and has limited leeway for investment
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+34.84% | 228M | C+ | ||
+24.66% | 88.38B | C+ | ||
-21.76% | 77.56B | B- | ||
+6.83% | 28.74B | C+ | ||
+7.23% | 18.45B | A- | ||
-13.50% | 16.57B | B | ||
+77.51% | 13.65B | C- | ||
+76.96% | 13.06B | C+ | ||
+4.35% | 12.61B | A- | ||
+36.67% | 12.56B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PIHLIS Stock
- Ratings Pihlajalinna Oyj